Ajanta Pharma has announced its earnings conference call schedule for Q3FY26 results discussion, filing the notification under Regulation 30 of SEBI listing requirements on January 12, 2026. The pharmaceutical company will release its unaudited financial results for the third quarter of fiscal year 2026 followed by an investor interaction session.

Conference Call Details

The earnings conference call is scheduled for January 30, 2026, providing investors and analysts an opportunity to engage with the company's leadership team regarding financial performance and business developments.

Dial-in Access Options

The company has arranged multiple access methods to accommodate participants from different regions. A Diamond pass registration system offers faster connectivity for convenience.

Primary Access Numbers

• Universal Access: (+91 22 6280 1542) and (+91 22 7115 8372)
• Diamond pass registration available for expedited access

International Toll-Free Numbers

• USA: 18667462133
• UK: 08081011573
• Hong Kong: 800964448
• Singapore: 8001012045

Registration Process

Participants can register through the Diamond pass link to receive a calendar invite with passcode and PIN number. The access credentials will be activated 30 minutes before the scheduled conference time. The registration system includes step-by-step instructions for dialing in and reconnecting if disconnected.

Post-Call Availability

The earnings call playback will be accessible on the company's website at www.ajantapharma.com within 120 minutes after the session concludes. A complete transcript of the conference call will also be made available on the same platform.

Investor Relations Contacts

For queries related to the earnings call, investors can reach out to the designated investor relations team:

• Rajeev Agarwal: rajeev.agarwal@ajantapharma.com
• Abhineet Kumar: abhineet.kumar@ajantapharma.com

The announcement was signed by Gaurang Shah, Sr. VP – Legal & Company Secretary, ensuring compliance with regulatory disclosure requirements.

Motilal Oswal has maintained its 'Buy' rating on Ajanta Pharma with a target price of ₹3,145, citing strategic initiatives across India, Asia, and Africa markets. The brokerage firm indicates confidence in the pharmaceutical company's growth prospects with the updated price target reflecting positive expectations.

Target Price and Rating Details

The brokerage's recommendation includes specific financial targets for the pharmaceutical company:

Strategic Market Focus

The brokerage firm highlights that Ajanta Pharma is implementing multiple strategic initiatives across its focus branded generics markets. The company's primary geographic focus areas include:

• India
• Asia
• Africa

These strategic initiatives are positioned to help the pharmaceutical company sustain robust industry outperformance, according to the analyst assessment.

Market Positioning

The maintained 'Buy' recommendation with the specified target price suggests that Motilal Oswal views Ajanta Pharma's current market positioning and strategic direction favorably within the branded generics pharmaceutical segment. The brokerage's positive outlook is supported by Ajanta Pharma's targeted approach in key markets and its potential for continued growth in the pharmaceutical industry.